Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;59(4):541-553.
doi: 10.1007/s11262-023-02006-x. Epub 2023 May 27.

Genetic variability and mutation of Epstein‒Barr virus (EBV)-encoded LMP-1 and BHRF-1 genes in EBV-infected patients: identification of precise targets for development of personalized EBV vaccines

Affiliations

Genetic variability and mutation of Epstein‒Barr virus (EBV)-encoded LMP-1 and BHRF-1 genes in EBV-infected patients: identification of precise targets for development of personalized EBV vaccines

Yue Wang et al. Virus Genes. 2023 Aug.

Abstract

The critical Epstein‒Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) and BamHI fragment H rightward open reading frame 1 (BHRF-1) genes affect EBV-mediated malignant transformation and virus replication during EBV infection. Therefore, these two genes are considered ideal targets for EBV vaccine development. However, gene mutations in LMP-1 and BHRF-1 in different cohorts may affect the biological functions of EBV, which would seriously hinder development of personalized vaccines for EBV. In the present study, by performing nested polymerase chain reaction (nested PCR) and DNA sequence techniques, we analyzed the nucleotide variability and phylogeny of LMP-1 containing a 30 bp deletion region (del-LMP-1) and BHRF-1 in EBV-infected patients (N = 382) and healthy persons receiving physical examination (N = 98; defined as the control group) in Yunnan Province, China. Three BHRF-1 subtypes were identified in this study: 79V88V, 79L88L, and 79V88L, with mutation frequencies of 58.59%, 24.24%, and 17.17%, respectively. Compared with the control group, the distribution of BHRF-1 subtypes of the three groups showed no significant difference, suggesting that BHRF-1 is highly conserved in EBV-related samples. In addition, a short fragment of del-LMP-1 was found in 133 cases, and the nucleotide variation rate was 87.50% (133/152). For del-LMP-1, a significant distribution in three groups was detected, as characterized by a high mutation rate. In conclusion, our study illustrates gene variability and mutations of EBV-encoded del-LMP-1 and BHRF-1 in clinical samples. Highly mutated LMP-1 might be associated with various types of EBV-related diseases, indicating that BHRF-1 combined with LMP-1 may be used as an ideal target for development of EBV personalized vaccines.

Keywords: BHRF-1 gene; Epstein‒Barr virus; Gene variation; LMP-1 gene; Mutations.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Phylogenetic tree constructed from LMP-1 carboxy terminal nucleotide sequences of 155 EBV sample variants (leukemia labeled ▲, lymphoma labeled ■, the control group labeled ◆). Others are standard sequences, including USA (No. U08278), Hong Kong (No. HE582207, No. HE582389). The phylogenetic trees were constructed by the neighbor-joining method and the Kimura 2-parameter model by the MEGA package
Fig. 2
Fig. 2
Phylogenetic tree constructed from BHRF1 nucleotide sequences of 107 EBV sample variants. (leukemia labeled ▲, lymphoma labeled ■, the control group labeled ◆). Others are standard sequences, including China (No. AB850647), Ghana (No. DQ279927), Japan (No. AP015016, No. KC207813 and NC007605), Hong Kong (No. KF373730), and South Korea (No. KP735248). The phylogenetic trees were constructed by the neighbor-joining method and the Kimura 2-parameter model by the MEGA package

Similar articles

Cited by

References

    1. Kaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res. 2012;72(14):3445–3450. doi: 10.1158/0008-5472.Can-11-3919. - DOI - PubMed
    1. Lorenzetti MA, Altcheh J, Moroni S, Moscatelli G, Chabay PA, Preciado MV. EBNA1 sequences in Argentinean pediatric acute and latent Epstein-Barr virus infection reflect circulation of novel South American variants. J Med Virol. 2010;82(10):1730–1738. doi: 10.1002/jmv.21871. - DOI - PubMed
    1. Moss WN, Steitz JA. Genome-wide analyses of Epstein-Barr virus reveal conserved RNA structures and a novel stable intronic sequence RNA. BMC Genomics. 2013;14:543. doi: 10.1186/1471-2164-14-543. - DOI - PMC - PubMed
    1. Kerr JR. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. J Clin Pathol. 2019;72(10):651–658. doi: 10.1136/jclinpath-2019-205822. - DOI - PubMed
    1. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003;22(33):5108–5121. doi: 10.1038/sj.onc.1206556. - DOI - PubMed